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42 (16.0%) patients self monitor their glucose level. The most frequently reported 
factor affecting adherence is high cost of drug therapy, 118 (44.8%), and 
forgetfulness, 99 (37.6%). Most of the patients, 201 (76.4%), have developed one 
complication or the other such as hypertension and glaucoma. CONCLUSIONS: 
There is poor adherence to anti-diabetic therapy among the patients. Financial 
constraint was found to be the most important factor affecting optimal 
adherence to therapy.  
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OBJECTIVES: To examine adherence to oral hypoglycemics among Mississippi 
Medicaid beneficiaries and to evaluate the need for case-mix adjustment when 
examining disparities among counties. METHODS: The study was a retrospective 
analysis of Mississippi Medicaid claims data from 2008-2011. Beneficiaries were 
included in the analysis if they had at least two claims for oral hypoglycemics, 
had 90 or more days of therapy, were at least 18 years old, were not dual-eligible, 
and were not in long term care. Medication adherence was measured using 
Proportion of Days Covered (PDC) with a gap of 60 days being considered a 
discontinuation of therapy. PDC was calculated for each drug being taken and an 
average PDC was computed for each beneficiary for the time on any therapy. 
Beneficiaries with a PDC greater than 80% were considered to be compliant to 
therapy. Overall comorbidity was measured with an RxRisk score. Percentage of 
beneficiaries compliant in each county was calculated. Counties were classified 
as high, medium and low compliance. A multivariable logistic regression model 
was used to assess the relationship between compliance and beneficiaries’ age, 
sex, race and comorbidities. The relationships among county compliance level 
and beneficiary characteristics associated with compliance were evaluated to 
determine case-mix confounders that need to be adjusted for in evaluating 
county level disparities. RESULTS: Percentage of compliant beneficiaries in the 
counties ranged from 33.3% to 66.7%. Beneficiary characteristics related to 
compliance were gender (odds ratio for male to female = 0.870), race (odds ratio 
for African-Americans to Caucasians = 0.647), and RxRisk score (odds ratio for 
score of 0 to 6+ = 0.717). Race and RxRisk scores were significantly related to 
county compliance levels. CONCLUSIONS: Beneficiary characteristics are strong 
predictors of compliance. Any evaluation of county level disparities in adherence 
rates must use adjustments for variations in the patient mix among the 
counties.  
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OBJECTIVES: The association between anti-diabetic adherence, weight loss, and 
glycemic control in patients with type 2 diabetes (T2DM) remains largely 
uncharacterized. This study examined the relationships between these variables 
in T2DM patients in an integrated health system. METHODS: This was a 
historical cohort study of patients treated in the Geisinger Health System. 
Included patients were ≥18 years, with T2DM, prescribed a class of anti-diabetic 
not previously prescribed (index date) between 11/1/10-4/30/11, with HbA1c and 
weight values at index date and 6-months follow-up, and had Geisinger Health 
Plan insurance with ≥1 claim for the index date medication. Anti-diabetics were 
grouped as weight loss (metformin and GLP-1 agonists) versus weight 
gain/neutral (sulfonylureas, thiazolidinediones, DPP-4 inhibitors, insulin, and 
others) to help control for weight effects of drug therapy. Adherence was 
calculated using the modified Medication Possession Ratio (mMPR) with a score 
≥0.8 considered adherent. The primary outcomes were weight loss ≥3% and 
HbA1c control (<7.0%) at 6 months follow-up. A structural equation model (SEM) 
was used to simultaneously assess the associations between claims adherence, 
weight loss, and HbA1c control. RESULTS: There were 166 patients included with 
a mean (SD) age of 61.1 (12.1) years, 56% were women, 98.8% were white, 58 were 
prescribed metformin or a GLP-1, and 108 were prescribed a sulfonylurea, 
thiazolidinedione, DPP-4 inhibitor, insulin, or other class. Adherence per mMPR 
was high with 77.1% of patients classified as adherent with no significant 
difference between anti-diabetic groups. Results of the SEM showed that both 
anti-diabetic adherence (OR 2.71 95%CI 1.22-5.98) and weight loss ≥3% (OR 2.99 
95%CI 1.45-6.17) were associated with HbA1c control. CONCLUSIONS: This study 
adds to the body of literature highlighting the importance of weight loss and 
adherence in glycemic control. It also emphasizes the importance of anti-
diabetic agent selection and strategies promoting adherence and weight 
management goals.  
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OBJECTIVES: The Morisky Medication Adherence Scale (MMAS) provides a 
unique perspective on adherence because of its patient-reported nature. 
However, as it is not a condition-specific instrument, evidence of its reliability 
and validity within the population of interest must be obtained. This study 
examined the psychometric properties of the recently developed eight-item 
MMAS (MMAS-8) among those with type 2 diabetes (T2D) using insulin. 
METHODS: Data from the US 2012 National Health and Wellness Survey (NHWS) 
were used (N=71,141). Only respondents who reported a diagnosis of T2D, were 
currently using an insulin (any type), and reported their last value of HbA1c were 
included (n=1,198). Among this subsample, the reliability and validity of the 
MMAS-8 (when asked only about diabetes medications) were examined using 
both classic test theory and item response theory (IRT) analyses. RESULTS: A 
total of 61.44% of respondents were male and the mean age was 60.65 (standard 
deviation = 10.74). Engagement of non-adherent behaviors (the individual items 
of the MMAS-8) varied considerably from “stopping medication when feeling 
worse” (5.76%) to “having difficulty remembering to take all your medications” 
(32.22%). Internal consistency was adequate (Cronbach’s α=0.68), though would 
have been improved upon removal of the “did you take your medicine yesterday” 
item (α=0.70 if removed). One factor was retained using exploratory factor 
analysis (eigenvalue=1.80). In IRT analyses, most items exhibited solid 
psychometric properties (e.g., discrimination > 1.40); however, “did you take your 
medicine yesterday”, provided little information (discrimination=0.20; 
information=0.02). Overall, the MMAS-8 functioned best when distinguishing 
among those with above average non-adherence (Θ>0). CONCLUSIONS: These 
results suggest the MMAS-8 is a reliable and valid instrument to use to assess 
non-adherence, though certain items are less useful than others for this 
population. Despite its generic nature, the MMAS-8 should be considered as an 
adherence measurement tool among those with T2D using insulin.  
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OBJECTIVES: Patients with type-2 diabetes mellitus (T2DM) are at increased risk 
of stroke or myocardial infarction (MI) resulting in decrements in their health-
related quality of life. A systematic literature review identified estimates of 
utility decrements for these events in patients with T2DM to better understand 
the impact of avoiding or delaying them with treatment. METHODS: Electronic 
databases (2001-2011) and conference abstracts (2009-2011) in English were 
searched for utility-elicitation studies in T2DM and for cost-effectiveness 
analyses that included disutility estimates for stroke and MI. RESULTS: Nine 
utility-estimation studies using data from 11 countries were identified. Seven of 
these studies presented results adjusted for confounding variables including age 
and other comorbidities. Of those, two also adjusted for time since the event or 
event severity. Disutilities ranged from 0.035 to 0.129 for MI and from 0.044 to 
0.269 for stroke. One study presented disutilities for an event experienced the 
previous year (MI, 0.081 - 0.129; stroke, 0.091 - 0.181) and >1 year ago (MI, 0.042 - 
0.078; stroke, 0.069 - 0.269). The study presenting estimates by event severity 
adjusted for confounding variables had disutilities of 0.044 for stroke or transient 
ischemic attack without disability and 0.072 for stroke with residual disability. Of 
the 15 economic evaluations identified that included estimates of disutilities for 
MI and/or stroke, 12 used values from one of the utility-estimation studies 
described above. Two used disutilities from US studies in patients with any type 
of diabetes, and one used general population disutilities. CONCLUSIONS: The 
wide range of utility estimates for MI or stroke in T2DM patients could impact 
the results of cost-effectiveness analyses for new treatments that avoid or delay 
these events and calls for research to create consistent estimates, accounting for 
event severity and valuing event sequelae over time, such as poststroke 
disability.  
 
PDB70  
PATIENT-REPORTED OUTCOMES (PROS) IN DIABETES CLINICAL TRIALS  
Barsdorf AI1, Rubinstein E2, Jaksa A2 
1Pfizer Inc, New York, NY, USA, 2Context Matters, Inc., New York, NY, USA  
OBJECTIVES: To assess prevalence and type of Patient-Reported Outcomes 
(PROs) in Type 2 Diabetes clinical trials. METHODS: A search of 
www.clinicaltrials.gov was conducted using the search criteria of Type-2 
diabetes (T2DM) as the disease and drug as the intervention, in addition to 
limiting the studies to Phase 3. This resulted in 810 trials. Trials were excluded if 
any of the following exclusion criteria were met: sample size <50, start date 
before 2000, main condition other than T2DM, and trial did not include clinical 
outcomes. Phase 2/3 studies, pediatrics trials, and both double-blind and open-
label studies were included. The remaining 632 trials were then assessed  
for prevalence and type of PROs. RESULTS: Only 47 (7.4%) of trials in the sample 
used PROs. There is no discernable trend for PRO use over time. For these  
47 trials, 1.9 PROs were used on average, with a range of 1 to 7 PROs. A total of  
90 PROs were included in these 47 trials. Forty-three (48%) of these PROs 
measured Health-Related Quality of Life (HRQL)/Utilities, 22 (24%) measured 
treatment satisfaction, five (6%) were unknown. Within the HRQL measures,  
37% (16) were diabetes-specific, 37% (16) were generic (e.g., SF-36), and the 
remaining 26% of PROs were not specified. Among treatment satisfaction, 82% 
were diabetes-specific. Thirty-three (70%) of the studies using PROs were for 
drugs that are injectables (i.e., not oral). CONCLUSIONS: PRO use in T2DM 
clinical trials remains low. Despite their underuse, the need to assess 
effectiveness of an intervention from a patient perspective continues to grow in 
relevance. Although there are a host of diabetes-specific PROs available, the 
development of a clinical trial-specific, user-friendly instrument may be needed 
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given the increase in medicines, especially injectables, coming to market in the 
future.  
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OBJECTIVES: Pharmacoeconomic models in diabetes link blood glucose control 
as measured by hemoglobin A1c to diabetes-related complications. Despite 
advances in diabetes modeling, there is limited research on the relationship 
between A1c and health-related quality of life (HRQoL) that is independent of 
diabetes-related complications. Our objective was to quantify the cross-sectional 
relationship between A1c and HRQoL utility scores in adult type-1 diabetes (T1D) 
patients, after adjusting for diabetes-related complications. METHODS: The 
EuroQoL-5 dimensions (EQ-5D) questionnaire was administered to adult T1D 
patients during one clinic visit at the University of Colorado Barbara Davis 
Center for Diabetes (BDC) from November 2011 – July 2012. We combined 
individual-level data from the EQ-5D questionnaire with A1c data from the BDC 
medical record. Utility scores were derived using the US time-tradeoff valuation 
of the EQ-5D. Unadjusted mean utility scores were estimated for the overall 
population and stratified by A1c. We used ordinary least squares regression with 
robust standard errors to estimate the cross-sectional relationship between A1c 
and utility, adjusting for demographic variables and diabetes-related 
complications. RESULTS: Mean (SD) age in years for the population (N = 176) was 
38 (12.2); duration of diabetes in years was 22 (12.1); and number of chronic 
conditions other than diabetes was 2.7 (2.0). Unadjusted mean (SD) utility was 
0.94 (0.09) for those with A1c levels < 7% (n = 54); 0.89 (0.15) for those with A1c ≥ 
7% (n = 122); and 0.91 (0.14) for all patients. On average, a 1% absolute increase in 
A1c was associated with a significant disutility of -0.03 (95% CI: -0.06, -0.006), 
after adjustment. CONCLUSIONS: Findings suggest that after adjusting for 
diabetes-related complications, poor blood glucose control is associated with 
decrements in utility not currently captured in existing diabetes 
pharmacoeconomic models. Longitudinal research is needed to strengthen this 
cross-sectional evidence on the relationship between A1c and HRQoL utility.  
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OBJECTIVES: Generic health measures are routinely used to assess HRQoL in 
population studies of persons with diabetes and other chronic illness. It is not 
known whether these measures provide consistent results in assessing HRQoL in 
patients with diabetes or whether these measures are able to discriminate 
between the HRQoL of persons with and without diabetes and across levels of 
diabetes severity. To compare HRQoL differences across levels of diabetes 
severity using six generic indexes and to examine the generic indexes ability to 
discriminate between the HRQoL levels across diabetes severity. METHODS: The 
National Health Measurement Study is a population-based, cross-sectional 
survey of 3844 non-institutionalized adults in the United States. Participants 
completed six generic measures of HRQoL—EQ-5D, HUI2, HUI3, QWB-SA, SF-36v2 
(yielding PCS, MCS, and SF-6D), and HALex. Diabetes severity was classified as 
non-diabetic, diabetes without medication, diabetes with medication, and 
diabetes with insulin. Weighted mean difference scores between each diabetes 
category adjusted for age, sex, and gender were calculated for each index. Effect 
sizes were calculated for each index between each diabetes group by 
standardizing to the population standard deviation among those without 
diabetes. RESULTS: A total of 726 (19%, unweighted) individuals self-reported 
diabetes. Across all indexes persons with diabetes demonstrated statistically 
significantly lower unadjusted and adjusted HRQoL scores than those without 
diabetes (p < 0.001). The HALex had the highest effect sizes for all comparisons 
between diabetes categories (ranging from 0.16 through 1.30), followed by the SF-
36v2 PCS (ranging from 0.24 through 0.98), and the SF-36v2 MCS (ranging from 
0.06 through 0.57). CONCLUSIONS: Results demonstrate the ability for generic 
HRQoL indexes to differentiate between persons with and without self-reported 
diabetes. The HALex was consistently better at differentiating among diabetes 
severity as. This study indicates that generic indexes are useful for evaluating 
HRQoL even in a diabetes-specific context.  
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OBJECTIVES: Islet transplantation is an accepted transplantation method in type 
I Diabetes Mellitus, yet islet survival is hampered due to an insufficient 
transplantation site and severe immunological and inflammatory responses. The 
development of a bio-artificial pancreas (BAP) may contribute to transplanted 
islet functionality and survival. The objective of this study is to identify the most 
important transplantation characteristics and to asses patients’ and 
endocrinologists´ preferences for three potential BAP scenarios in order to guide 
further development. METHODS: The current standard of care and 
characteristics that determine clinical decisions for a particular transplantation 
method were analysed based on a literature search, semi-structured interviews 
and focus groups. A decision tree was constructed covering the main attributes 
effectiveness, patient safety, impact of the treatment for the patient and the 
required amount of donor material. The analytic hierarchy process was used to 
obtain the relative weights for each defined attribute in type I DM patients (n=21) 
and endocrinologists (n=12). Based on these weights, overall preferences for 
three potential BAP scenarios were calculated and compared to conventional 
pancreas and islets transplantation. RESULTS: The three most important 
treatment attributes are the effectiveness of the transplant for glucose control, 
patient safety and the surgical procedure. However, there were considerable 
differences between patients and endocrinologists in the importance of 
effectiveness of the transplant (weights were 0.471 and 0.257 respectively) and 
patient safety (0.331 and 0.423). While considering both endocrinologists’ and 
patients’ preferences, all three BAP scenarios assessed gained a higher overall 
preference in comparison to conventional islet transplantation. CONCLUSIONS: 
This study indicates the prospects of BAP development. Nevertheless, the study 
also highlights the discrepancies between endocrinologists’ and type 1 diabetes 
patients’ preferences. In the future, BAP developers can benefit from this 
multidisciplinary approach by critically reviewing their BAP design, in view of 
patient safety and clinical performance.  
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OBJECTIVES: Patient-centered outcomes research (PCOR) aims to incorporate 
patient preference into the evaluation of competing therapies. We sought to 
identify and categorize methods used to assess patient preferences in the 
literature, focusing on medication preference of adults with type-2 diabetes. 
METHODS: Studies of patient preferences for type-2 diabetes medications were 
identified from the PubMed, EMBASE, CINAHL and EconLit databases using a 
registered study protocol (CRD42012002285) and aided by the PRISMA guidelines. 
Studies were included if they presented data on the preferences of adults with 
type-2 diabetes and excluded if they had no primary data on preference, focused 
only on behavioral change or on treatments for complications or co-morbid 
conditions. Two investigators reviewed titles, abstracts, and articles sequentially 
to select studies based on the inclusion and exclusion criteria. Disagreements 
were resolved by consensus. Data were abstracted into standardized forms and 
summary statistics were calculated. RESULTS: In total, 1883 unique papers were 
identified, of which 57 published between 1985 and 2011 met the selection 
criteria. Of these, 40% could be categorized as being primarily focused on 
preferences, using systematic methods such as conjoint analysis (n=10), 
contingent valuation (n=1), qualitative research (n=1), revealed preference (n=5), 
standard gamble (n=2), and time trade-off (n=6). The remaining 35 papers had 
preference data as a secondary aim, asking patients about their preferences 
and/or willingness to continue using or recommend products studied in a 
clinical trial. CONCLUSIONS: While an extensive literature focused on 
medication preferences of patients with type-2 diabetes can be identified, 
evidence synthesis is hindered by the diverse range of methods, including a 
majority of papers that assess preferences in an unsystematic way. Further 
research is needed to compare results of different methods and to assess the 
quality of preference studies.  
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OBJECTIVES: Severe hypoglycemic events are serious yet underreported 
condition that may lead to morbidity and even mortality. These events are an 
important limiting factor to good glycemic control. The objective of this study 
was to determine self-reported severe hypoglycemic rate in T2DM, basal insulin 
users in the National Health and Wellness Survey (NHWS) US population. 
METHODS: NHWS is a large international self-reported, real-world, patient-level 
survey which collects information on metrics such as patients’ demographics, 
behaviors and attitudes towards diseases in over 165 therapeutic conditions. We 
used an extract from the 2010 NHWS dataset composed of T2DM patients who 
were taking basal insulin monotherapy or in combination with oral anti-diabetic 
medications (OAD). The respondents (n=425) recalled number of severe 
hypoglycemic events they had in the last 4 weeks and 6 months prior to the 
survey. We analyzed event rates using multiple regression. RESULTS: Fifty-one 
percent of respondents were female and the mean age was 61.6 (SD=10.03). The 
overall severe hypoglycemia event rate for the 4 week and 6 month recall periods 
were 0.34 and 0.27 per patient-year, respectively. Among basal insulin only users 
(n=60), the event rates were 0.43 (6 month recall) and 0.37 (4 week recall) per 
patient-year. Among basal insulin plus OAD users (n=365), the rates were 0.32 (6 
month recall) and 0.26 (4 week recall) per patient-year. The relationship between 
presence of severe hypoglycemia rates and insulin treatment categories after 
adjusting for the covariates were non-significant. CONCLUSIONS: Basal insulin 
only users reported higher rates of severe hypoglycemia than basal insulin plus 
OAD users, but the difference was not statistically significant likely due to small 
sample size. Recall bias could also contribute to differences between the rates. 
Overall, our rates were higher than what have been reported in the literature 
with claims data, suggesting that severe hypoglycemia may be underreported.  
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